- Synthesis and Evaluation of Water-Soluble Prodrugs of Ursodeoxycholic Acid (UDCA), an Anti-apoptotic Bile Acid
-
Ursodeoxycholic acid (UDCA) is a bile acid with demonstrated anti-apoptotic activity in both invitro and invivo models. However, its utility is hampered by limited aqueous solubility. As such, water-soluble prodrugs of UDCA could have an advantage over the parent bile acid in indications where intravenous administration might be preferable, such as decreasing damage from stroke or acute kidney injury. Five phosphate prodrugs were synthesized, including one incorporating a novel phosphoryloxymethyl carboxylate (POMC) moiety. These prodrugs were highly water-soluble, but showed significant differences in chemical stability, with oxymethylphosphate prodrugs being the most unstable. In a series of NMR experiments, the POMC prodrug was bioactivated to UDCA by alkaline phosphatase (AP) faster than a prodrug containing a phosphate directly attached to the alcohol at the 3-position of UDCA. Both of these prodrugs showed significant anti-apoptotic activity in a series of invitro assays, although the POMC prodrug required the addition of AP for activity, while the other compound was active without exogenous AP.
- Dosa, Peter I.,Ward, Tim,Castro, Rui E.,Rodrigues, Cecilia M. P.,Steer, Clifford J.
-
-
Read Online
- COMPOSITIONS FOR THE PREVENTION AND TREATMENT OF PARKINSON'S DISEASE
-
Methods of preventing or retarding or reversing or abolishing the onset of Parkinson's and other neurodegenerative diseases are discussed.
- -
-
Paragraph 14; 26
(2019/10/19)
-
- WATER-SOLUBLE URSODEOXYCHOLIC ACID PRODRUGS
-
Ursodeoxycholic acid (UDCA) is a bile acid with demonstrated anti-apoptotic activity in both in vitro and in vivo models. Water-soluble prodrugs of UDCA for use in indications where intravenous administration of UDCA may be preferable, such as reducing damage from stroke or acute kidney injury, are disclosed. The disclosed prodrugs showed significant anti-apoptotic activity in a series of in vitro assays.
- -
-
Paragraph 0053; sheet 5
(2014/11/11)
-